Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

The artificial pancreas in 2017

The year of transition from research to clinical practice

Nature Reviews Endocrinology volume 14, pages 74–76 (2018)Cite this article

Subjects

The artificial pancreas — the automated closed-loop control of diabetes mellitus — made its first outpatient strides in 2011. In 2017, the results of long-term clinical trials on the artificial pancreas were published, the first hybrid commercial artificial pancreas system was approved and the artificial pancreas was tested under increasingly demanding conditions. Thus, artificial pancreas technology is here to stay.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Embedded and mobile artificial pancreas system configurations.

References

  1. Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinol. 7, 385–395 (2011).

    Article  CAS  Google Scholar 

  2. Cefalu, W. T. & Tamborlane, W. V. The artificial pancreas: are we there yet? Diabetes Care 37, 1182–1183 (2014).

    Article  Google Scholar 

  3. Kovatchev, B. P., Tamborlane, W. V., Cefalu, W. T. & Cobelli, C. The artificial pancreas in 2016: a digital treatment ecosystem for diabetes. Diabetes Care 39, 1123–1127 (2016).

    Article  Google Scholar 

  4. Bergenstal, R. M. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316, 1407–1408 (2016).

    Article  Google Scholar 

  5. Garg, S. K. et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol. Ther. 19, 155–163 (2017).

    Article  CAS  Google Scholar 

  6. Bally, L. et al. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol. 5, 261–270 (2017).

    Article  Google Scholar 

  7. Dassau, E. et al. 12-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia. Diabetes Care http://dx.doi.org/10.2337/dc17-1188 (2017).

  8. Dovc, K. et al. Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. Diabetologia 60, 2157–2167 (2017).

    Article  CAS  Google Scholar 

  9. Breton, M. D. et al. Closed loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study. Diabetes Care http://dx.doi.org/10.2337/dc17-0883 (2017).

  10. National Institutes of Health. Four pivotal NIH-funded artificial pancreas research efforts begin. NIH https://www.nih.gov/news-events/news-releases/four-pivotal-nih-funded-artificial-pancreas-research-efforts-begin (2017).

Download references

Acknowledgements

The author's work on closed-loop control is supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants DP3 DK101055, RO1 DK 085623 and UC4 108483 – the International Diabetes Closed-Loop Trial, and by the University of Virginia's Strategic Investment in Type 1 Diabetes.

Author information

Authors and Affiliations

  1. Center for Diabetes Technology, University of Virginia, POBox 400888, Charlottesville, 22908, Virginia, USA

    Boris Kovatchev

Authors
  1. Boris Kovatchev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Kovatchev.

Ethics declarations

Competing interests

B.K. has received speaking engagements/honoraria from Dexcom and Sanofi; research support managed by the University of Virginia from Ascensia Diabetes Care, Dexcom, Roche Diagnostics and Tandem Diabetes Care; patent royalties managed by the University of Virginia from Johnson & Johnson and Sanofi; and is shareholder/board member of TypeZero Technologies, Inc.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kovatchev, B. The year of transition from research to clinical practice. Nat Rev Endocrinol 14, 74–76 (2018). https://doi.org/10.1038/nrendo.2017.170

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2017.170

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing